Related Experiment Video
Updated: Sep 17, 2025

10:10
Spatiotemporally Controlled Nuclear Translocation of Guests in Living Cells Using Caged Molecular Glues as Photoactivatable Tags
Published on: January 17, 2019
10.7K
Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition
Georg Petzold1, Pablo Gainza1, Stefano Annunziato1
1Monte Rosa Therapeutics Inc, Boston, MA, USA.
Summary
Molecular glues targeting CRL4CRBN reprogram specificity to degrade proteins. This study expands the cereblon (CRBN) target space, identifying new recognition rules and over 1600 potential neosubstrates for drug development.
Area of Science:
- Molecular biology and pharmacology
- Protein degradation pathways
- Drug discovery and development
Background:
- The CRL4CRBN E3 ubiquitin ligase is a key target for molecular glue degraders.
- These compounds reprogram ligase specificity to induce degradation of neosubstrate proteins.
- Existing cereblon (CRBN) neosubstrates share a β-hairpin G-loop recognition motif.
Purpose of the Study:
- To systematically explore the CRBN target space beyond known motifs.
- To identify novel neosubstrates and binding mechanisms for CRL4CRBN.
- To establish a platform for developing next-generation molecular glue degraders.
Main Methods:
- Utilized computational mining with structure- and surface-based matchmaking algorithms.
- Analyzed protein structures to identify CRBN-compatible G-loop proteins.
- Investigated noncanonical binding modes, such as VAV1's molecular surface mimicry.
Main Results:
- Predicted over 1600 CRBN-compatible G-loop proteins in the human proteome.
- Discovered a novel helical G-loop motif for CRBN recognition.
- Identified VAV1 as a noncanonical neosubstrate with a unique binding mechanism.
Conclusions:
- Broadened the understanding of the CRBN target space and neosubstrate recognition rules.
- Demonstrated the potential for repurposing CRL4CRBN to target challenging proteins.
- Established a foundation for developing advanced molecular glue degraders for drug discovery.

